WASHINGTON (Reuters) – House Republicans were making headway in efforts to build support for a reworked plan to overhaul the U.S. healthcare system, but have not decided when to vote, House Speaker Paul Ryan said on Thursday.
(Reuters) – The U.S. Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc’s drug to treat a type of Batten disease, an extremely rare disorder that mainly impacts the nervous system.
LONDON (Reuters) – British biotech firm Synairgen lost nearly half its value on Thursday as partner AstraZeneca pulled the plug on an experimental drug designed to help patients fight common cold viruses.
ZURICH (Reuters) – Swiss drugmaker Roche, encouraged by better than expected first-quarter sales, said it was confident new drugs will help to deliver revenue and profit growth even as its older medicines take a hit from cheaper copies.
(Reuters) – U.S. biotechnology company Celgene Corp reported lower-than-expected sales, hurt in part by soft demand for its psoriasis treatment even as sales of its flagship drug Revlimid beat estimates.